Understand what your gut health results really mean
See your biomarkers in context with a comprehensive panel.
- CLIA-certified labs
- HIPAA compliant
- Personalized health protocol
Pinpointing a common Bacteroides-family resident
A phocaeicola dorei test measures the amount of a specific gut bacterium—formerly called Bacteroides dorei—in your stool. Most labs quantify it by sequencing DNA from the sample, either with targeted 16S rRNA profiling or deeper metagenomic analysis. Because the short 16S V4 region can blur P. dorei with its close cousin P. vulgatus, some reports use longer-read sequencing or a species‑specific qPCR to improve specificity. Results show the relative abundance (your percentage compared with total microbes), reflecting your current microbiome state rather than a fixed trait. The species’ modern taxonomy places Bacteroides dorei within the Phocaeicola genus, so you may see either name in reports.
Why does this niche species matter? Phocaeicola dorei participates in breaking down complex carbohydrates and contributes to short‑chain fatty acid pools that help fuel colon cells, calm immune signaling, and support the gut barrier. It’s one of the common Bacteroidetes players in human stool—especially alongside P. vulgatus—so its level gives a window into a “Bacteroides‑forward” ecology that influences digestion, metabolic tone, and aspects of immune education. As with all microbiome measures, interpretation lives in context: diet, geography, and life stage can reshape what “balanced” looks like for you.
Why a Bacteroides-forward signal is worth reading
Testing connects a real bacterium to real‑world questions: Is your gut community diversified and stable, or leaning heavily on a few dominant species? Higher P. dorei often rides with a Bacteroides‑dominant pattern shaped by low fiber, higher fat/protein eating, and recent antibiotics. That profile can coincide with lower overall diversity—think lots of one artist on your playlist—which may mean less functional redundancy for tasks like fiber fermentation and barrier support. In early‑life research, a transient spike in B. dorei (the prior name) preceded islet autoimmunity in genetically high‑risk Finnish infants, suggesting a potential early microbial signal though not proof of causation. In parallel, Bacteroides lipopolysaccharide (LPS) appears less immunostimulatory than E. coli LPS, which may alter innate “training” in infancy—again, a mechanistic clue rather than a clinical directive.
Zoom out and P. dorei becomes a marker of systems biology, not a verdict. The P. dorei–P. vulgatus duo is among the most ubiquitous gut residents worldwide, evolving with us and adapting to our diets. Watching this signal over time helps you see how fiber intake, diversity of plant foods, and recovery after antibiotics show up in your microbiome. The goal isn’t a perfect number but patterns: how your gut ecosystem responds, stabilizes, and supports digestion, energy, and immune steadiness as life changes.
Test 100+ biomarkers
One blood draw. A full picture of your health, explained in plain language.
Test 100+ biomarkers
One blood draw. A full picture of your health, explained in plain language.
Reading the number in community context
Your results typically report P. dorei as a proportion of total microbes, sometimes benchmarked to a reference population. In many healthy adults, moderate representation of P. dorei within a diverse community is common. When P. dorei is high alongside other Bacteroides, it often signals a Bacteroides‑dominant enteric pattern, which can occur with lower fiber or after antibiotics; when it’s very low amid rich diversity, you may be seeing a Prevotella‑ or Firmicutes‑leaning pattern. “Normal” varies widely by diet, geography, and life stage, so it’s more about the community context than a single cut‑off.
Balanced ranges usually imply efficient carbohydrate breakdown, steady short‑chain fatty acid production, and a calm barrier. If P. dorei is disproportionately high, that can coincide with lower diversity or inflammation‑prone patterns in some settings; if very low, you may simply reside in a different, equally viable “ecotype.” In infants with specific genetics, research linked a transient surge in B. dorei to later islet autoimmunity, but that association does not establish causation and does not translate into stand‑alone screening or treatment decisions.
Big picture: P. dorei is most useful when viewed alongside other reads—overall diversity, other keystone species, stool inflammatory markers, and metabolic labs—and interpreted over time. Because most assays report relative abundance, it’s helpful to track trends and correlate with real changes in diet, stress, sleep, and medication use. That’s how you turn a single species into practical insight about digestion, energy, and long‑term gut resilience.
Credibility cues and test limitations
Selected research touchpoints
Why two Phocaeicola dorei tests can disagree
Taxonomy matters: Bacteroides dorei has been reclassified as Phocaeicola dorei, so reports may use either name. P. dorei and P. vulgatus are closely related; short‑read 16S (V4) alone may not separate them cleanly, and labs often use longer reads or species‑specific assays to improve resolution. Stool testing reflects relative abundance rather than absolute counts unless targeted qPCR is included. Day‑to‑day variation, sample handling, and lab pipelines can shift percentages. Finally, associations are not causation—P. dorei is a helpful lens on ecology and immune tone, not a diagnosis or a treatment target.
Frequently Asked Questions
References
- Davis-Richardson AG, Ardissone AN, Dias R, Simell V, Leonard MT, Kemppainen KM, Drew JC, Schatz D, Atkinson MA, Kolaczkowski B, Ilonen J, Knip M, Toppari J, Nurminen N, Hyöty H, Veijola R, Simell T, Mykkänen J, Simell O, Triplett EW (2014). Bacteroides dorei dominates gut microbiome prior to autoimmunity in Finnish children at high risk for type 1 diabetes. *Frontiers in Microbiology*, *5*, 678. https://doi.org/10.3389/fmicb.2014.00678
- Vatanen T, Kostic AD, d'Hennezel E, Siljander H, Franzosa EA, Yassour M, Kolde R, Vlamakis H, Arthur TD, Hämäläinen AM, Peet A, Tillmann V, Uibo R, Mokurov S, Dorshakova N, Ilonen J, Virtanen SM, Szabo SJ, Porter JA, ... Xavier RJ (2016). Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. *Cell*, *165*(4), 842-853. https://doi.org/10.1016/j.cell.2016.04.007
- Fusco W, Lorenzo MB, Cintoni M, Porcari S, Rinninella E, Kaitsas F, Lener E, Mele MC, Gasbarrini A, Collado MC, Cammarota G, Ianiro G (2023). Short-chain fatty-acid-producing bacteria: Key components of the human gut microbiota. *Nutrients*, *15*(9), 2211. https://doi.org/10.3390/nu15092211
- Jovel J, Patterson J, Wang W, Hotte N, O'Keefe S, Mitchel T, Perry T, Kao D, Mason AL, Madsen KL, Wong, G. K.-S. (2016). Characterization of the gut microbiome using 16S or shotgun metagenomics. *Frontiers in Microbiology*, *7*, 459. https://doi.org/10.3389/fmicb.2016.00459
- Drago L (2025). Navigating microbiome variability: Implications for research, diagnostics, and direct-to-consumer testing. *Frontiers in Microbiology*, *16*, 1580531. https://doi.org/10.3389/fmicb.2025.1580531

















